Full-Time
Updated on 8/11/2026
Develops medical devices for early detection
$63.6k - $99.5k/yr
Londonderry, NH, USA
In Person
Bachelor's
See people who can refer or advise you
Hologic develops medical technology to improve health through early detection and treatment. It designs, manufactures, and sells devices and diagnostic tests for breast and skeletal health, general diagnostics, GYN surgery, and medical aesthetics, sold to hospitals, labs, and providers with related services. Products enable screening, imaging, and guiding treatment in clinical settings. Its goal is to improve health outcomes by providing accurate diagnostics and reliable tools to support healthcare providers worldwide.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Santa Clara, null
Founded
1985
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
401(k) Retirement Plan
Performance Bonus
AI Cytology Screening market growth and challenges through 2033. Significant growth is on the horizon for the AI in cytology screening device market, with projections indicating an increase to over USD 330 million by 2033 as healthcare systems seek efficient diagnostic solutions. Key facts. * AI in cytology market projected to grow from $122.6M in 2026 to $330.9M by 2033 (CAGR 15.2%). * North America leads with 39.9% market share; Asia Pacific fastest-growing region indicates shifts. * High implementation costs hinder adoption in smaller labs, revealing vulnerability in market access. * Hologic's FDA approval for Genius system enhances competitive positioning in cervical cancer diagnostics. * Cloud-based solutions expected to grow rapidly, indicating strategic shift towards scalable AI technologies. Summary. The AI in cytology screening device market is poised for significant growth, projected to expand from USD 122.6 million in 2026 to USD 330.9 million by 2033, reflecting a compound annual growth rate (CAGR) of 15.2%. This growth is primarily driven by the increasing demand for improved diagnostic accuracy in the face of a global shortage of skilled cytologists. As healthcare providers seek to enhance laboratory efficiency and reduce the manual workload, the integration of artificial intelligence into cytology screening is becoming a critical strategy. North America currently leads the market, accounting for 39.9% of revenue share in 2025, with the U.S. being the largest contributor. The region's dominance is attributed to its robust research and development infrastructure, favorable reimbursement policies, and a high concentration of healthcare facilities equipped to adopt advanced technologies. Meanwhile, the Asia Pacific region is expected to experience the fastest growth, indicating a shift in market dynamics as emerging economies ramp up investments in healthcare technologies. The market is segmented into various product categories, with automated cytology screening systems holding a 33.7% revenue share in 2025. These systems leverage AI to automate the analysis of digitized slides, enhancing the speed and accuracy of abnormal cell detection. The gynecological cytology screening application is particularly significant, representing 75.6% of the market due to the ongoing emphasis on cervical cancer screening initiatives. Hospitals are the primary end-users, comprising 40.6% of the market, reflecting their critical role in implementing these technologies. The rising volume of cervical cancer screenings and preventive healthcare initiatives is intensifying the workload for pathology laboratories, which are often constrained by a lack of qualified specialists. This gap is driving investments in AI-assisted cytology solutions that can boost productivity and maintain diagnostic quality. For example, Hologic's Genius Digital Diagnostics System, which received FDA clearance, exemplifies how AI can enhance diagnostic workflows by automating slide evaluation and prioritizing high-risk cases for expert review. Despite the promising outlook, the market faces challenges, particularly the high implementation costs associated with transitioning to AI-enabled systems. Healthcare providers must invest in advanced imaging technologies, data storage solutions, and workforce training, which can be particularly burdensome for smaller institutions. This financial barrier limits the widespread adoption of AI technologies, especially in resource-constrained environments. The competitive landscape is characterized by ongoing innovation and strategic collaborations. Companies are focusing on expanding their product offerings to create integrated diagnostic solutions that address both workforce shortages and operational inefficiencies. The recent partnership between Synergy Laboratories and Hologic to implement AI-driven cervical cytology screening is a case in point, highlighting the growing commercial viability of these technologies. As the market evolves, the integration of AI into routine cytology practices is expected to accelerate. The demand for digital pathology solutions that facilitate remote consultations and centralized diagnostic services is increasing. This trend is likely to enhance the accessibility of advanced diagnostic technologies, particularly as cloud-based platforms become more prevalent. Looking ahead, the sustained emphasis on early cancer detection and the expansion of cervical cancer screening programs will create substantial opportunities for AI in cytology screening. Healthcare providers are increasingly prioritizing intelligent diagnostic solutions that can optimize testing capacity and improve the quality of diagnostic services. As regulatory approvals continue to support innovation, the market is set for robust growth, with AI-enabled cytology screening devices playing a pivotal role in transforming diagnostic workflows across global healthcare systems. The focus on developing scalable, integrated solutions will be critical for companies aiming to capitalize on this expanding market. Entities mentioned. Synergy Laboratories Aiforia Technologies Blackstone Genius Digital Diagnostics System Genius Cervical AI Aptima HPV Assay Technologies artificial intelligence deep learning digital pathology whole-slide imaging automated cytology screening systems AI cytology analysis software Organizations Key concepts. AI in cytology screening market growth diagnostic accuracy workforce shortages digital pathology integration cervical cancer screening automated slide evaluation regulatory impact Definitions. * AI in Cytology Screening - The use of artificial intelligence technologies to enhance the efficiency and accuracy of cytology diagnostics. * Automated Cytology Screening Systems - Systems that utilize AI to automate the analysis of cytological samples, improving diagnostic workflows. * Digital Pathology - The management and interpretation of pathology information in a digital format, facilitating remote consultations and integrated workflows. * Whole-Slide Imaging - A technology that captures high-resolution images of entire microscope slides, enabling digital analysis and storage. * Cervical Cancer Screening - The process of testing for cervical cancer in women, often using Pap smears and HPV testing. Use cases. * | Enhancing cervical cancer screening accuracy * | Automating routine cytology diagnostics * | Improving laboratory efficiency * | Facilitating remote consultations * | Optimizing specialist productivity * | Supporting workflow in pathology laboratories Frequently asked questions. What is driving the growth of AI in cytology screening? The growth is primarily driven by a shortage of skilled cytologists, increasing cervical cancer screening volumes, and the need for improved diagnostic accuracy and laboratory efficiency. How does AI improve diagnostic accuracy in cytology? AI enhances diagnostic accuracy by automating the analysis of digitized slides, prioritizing high-risk cases, and reducing the burden of manual evaluations, allowing specialists to focus on complex cases. What are the challenges in adopting AI-enabled cytology solutions? Challenges include high implementation costs, the need for robust digital pathology infrastructure, and the requirement for ongoing investments in training and regulatory compliance. What role do regulatory bodies play in the AI cytology market? Regulatory bodies like the U.S. FDA ensure the safety, performance, and clinical validation of AI-enabled diagnostic systems, fostering innovation and market confidence. What future trends are expected in the AI in cytology screening market? Future trends include increased integration of AI with digital pathology, expansion of cervical cancer screening programs, and advancements in cloud-based AI technologies to enhance diagnostic workflows.
Royal Medical Services launches advanced GEN 3 device for breast surgeries as first center in Kingdom of Bahrain Tuesday, August 4, 2026 The Royal Medical Services has launched the advanced GEN 3 device from Hologic, which is the first of its kind in the Kingdom of Bahrain, in a step that enhances the accuracy and efficiency of breast surgeries by employing the latest advanced medical technologies. The device relies on Magseed technology to accurately locate non-palpable tumors before and during surgery, and Magtrace technology to help identify the sentinel lymph node, in addition to providing real-time guidance to the surgeon through audio signals and precise digital readings, which supports reaching the target area during the surgical procedure. On this occasion, His Excellency Major General Doctor Sheikh Fahd bin Khalifa bin Salman Al Khalifa, Commander of the Royal Medical Services, affirmed that the launch of the GEN 3 device reflects the Royal Medical Services' keenness to keep pace with global developments in breast surgery techniques, and to provide advanced medical solutions that contribute to supporting therapeutic teams and enhancing the level of services provided to patients. His Excellency pointed out that investing in modern technologies represents part of the Royal Medical Services' strategy aimed at elevating medical performance levels and providing healthcare according to the highest standards. For his part, Edward Rowland, CEO of the Bahrain Oncology Center, praised this step, explaining that the GEN 3 system represents a qualitative addition to breast surgeries, as it provides advanced capabilities that reduce reliance on traditional methods, such as the use of wires and radioactive materials, which contributes to enhancing patient comfort and improving the efficiency of surgical procedures. He added that the new system supports the surgical team in providing a more advanced treatment experience, in line with the latest global practices in this field. Dr. Nouf Al-Shaibani, Head of the Women's Health Center at the Royal Medical Services and Consultant of General Surgery and Reconstructive Surgery at the Bahrain Oncology Center, explained that the GEN 3 device represents an important development in breast surgeries, as it helps the surgical team deal with delicate cases with a higher level of accuracy and control, and improves planning for surgical procedures. She affirmed that this technology contributes to enhancing the patient experience and supporting the achievement of better treatment outcomes through the integration of medical expertise and advanced technology. The launch of the GEN 3 device comes as an extension of the Royal Medical Services' efforts to develop the healthcare system, and to enhance its position as a leading institution that combines medical expertise and innovation to provide health services according to the highest international standards.
Ransomware Group Redact hits: hologic. HookPhish team Target organization Hologic hologic.com Healthcare Summary. In the latest cybersecurity news, Hologic - an organization based in US - has fallen victim to a ransomware attack conducted by the group Redact. This data breach, discovered on Jun 28, 2026, 08:38 UTC, underscores the increasing need for proactive cybersecurity defenses as Hookphish continue through 2026. Incident report. | Target Organization | Hologic | | Threat Group | Redact | | Summary | Sector: Medical Supplies | Revenue: $4B USD | | Date of Breach | Jun 28, 2026, 08:38 UTC | | Discovery Date | Jun 28, 2026, 08:38 UTC | | Region | US | | Target Domain | hologic.com | | Business Sector | Healthcare | How to reduce your ransomware risk. Most ransomware intrusions start with a stolen password or a phishing email. A few proactive steps sharply cut your exposure: * phishing simulations - close the gap attackers exploit. * awareness training - close the gap attackers exploit. Disclaimer. HookPhish does not engage in the exfiltration, downloading, taking, hosting, viewing, reposting, or disclosure of any stolen information. All breach data reported here is sourced from publicly available threat intelligence feeds for awareness purposes only.
Hologic highlights diagnostics portfolio, health care peers set the tone for the stock. 28.06.2026 - 11:22:29 | ad-hoc-news.de Hologic draws investor attention with its focus on women's health diagnostics as health care sector moves and S&P 500 dynamics shape the backdrop for the HOLX shares. By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-28, 11:22. Hologic (US4364401012) stands out in the U.S. health care sector with its focus on women's health diagnostics and surgical products. The stock is part of the medical devices peer group, alongside companies such as Abbott Laboratories and Boston Scientific, which anchor investor comparisons on the NASDAQ. Diagnostics player in a broad health care field. Hologic is best known for its breast and skeletal health, diagnostic, and gynecologic surgical solutions, positioning it firmly in the medical technology segment tied to hospitals and screening programs worldwide.The Hologic company site outlines its portfolio Hologic competes with larger diversified peers like Abbott and Becton Dickinson in diagnostics, while imaging rivals include GE HealthCare and Siemens Healthineers in key equipment categories.GE HealthCare's news room provides sector context Health care sector and index backdrop. Hologic shares trade on the NASDAQ in the U.S., where the health care cohort is a significant component of broad indices such as the S&P 500 and sector-focused funds tracking medical technology and services.NASDAQ data show Hologic quoted under ticker HOLX In this group, names like Abbott, Medtronic and Boston Scientific provide reference points for valuation metrics including price-to-earnings ratios and revenue growth within the medtech landscape.A Reuters note on Abbott's earnings illustrates sector trends Background and price data on Hologic. More news, key figures and historical performance for the Hologic shares are available in the dedicated topic section and via the company's investor relations pages. The product behind the stock. Hologic generates revenue from a portfolio centered on breast cancer screening and diagnostics, notably with its 3D mammography systems marketed under the Selenia Dimensions brand, as well as related biopsy devices and imaging software used in hospital and outpatient clinic settings.The Selenia Dimensions mammography system is detailed on Hologic's product pages Where the stock trades today. The Hologic shares (US4364401012) trade on NASDAQ under the ticker HOLX; the most recently verifiable quote centers around 76.01 US dollars, based on public price data as of a recent session in June 2026. Key data on the Hologic shares. * Company: Hologic, Inc. * ISIN: US4364401012 * WKN: 882399 * Ticker: HOLX * Trading venue: NASDAQ * Price (as of 2026-06-27, 16:00): 76.01 USD * Market cap: around 18 billion USD (as of late June 2026, based on public quote pages) * Sector / industry: Health Care, Medical Devices / Diagnostics * Index membership: S&P 500 * Next earnings date: not officially scheduled Disclaimer: This text is for informational purposes only and does not constitute investment advice, tax advice or a recommendation to buy or sell securities. All data are based on publicly available sources believed to be reliable; accuracy and completeness cannot be guaranteed. Investors should conduct their own research or consult a professional advisor before making investment decisions. Hologic stock: new analysis - 28 June. Fresh Hologic information released. What's the impact for investors? Our latest independent report examines recent figures and market trends. en | US4364401012 | HOLOGIC | boerse | 69645655 | bgmi
Hologic outlines growth strategy in women's health, shares on NASDAQ in medtech peer focus. 24.06.2026 - 09:14:44 | ad-hoc-news.de Hologic presents itself as a focused women's health medtech player with steady revenue growth and a clear diagnostic portfolio, while its shares trade on NASDAQ alongside peers such as Abbott and Roche. By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-24, 09:11. Hologic (US4364401012) positions itself as a focused medical technology company in women's health diagnostics and related products, with its shares listed on NASDAQ in the United States.Company overview from Hologic The group's long-term strategy centers on imaging, surgical and diagnostic solutions that aim to improve women's health outcomes. Long-term revenue development. Over the last 19 years, Hologic has grown its revenue by an average of around 12 percent per year, according to data aggregators that track the company's financials.Eulerpool revenue history for Hologic In 2026, sales are reported at roughly 4.1 billion US dollars, a modest increase versus the previous year's level. This revenue trajectory places Hologic among mid-sized medtech players that focus on diagnostics rather than large-scale pharmaceutical pipelines, in contrast to diversified peers such as Abbott Laboratories and Roche. The company's growth pattern reflects continued demand for breast health screening, gynecologic surgery tools and molecular diagnostics. Business focus in diagnostics. Hologic's portfolio is built around imaging, diagnostic and surgical platforms for women's health, including mammography systems, biopsy devices and minimally invasive gynecologic instruments.Hologic breast health solutions overview The group also provides molecular diagnostic assays and instrumentation used in laboratories for infectious disease testing and cervical cancer screening. The company emphasizes technology that aims to increase accuracy and efficiency in clinical workflows, particularly in breast cancer detection and gynecologic procedures. Its systems are typically sold to hospitals, imaging centers and laboratories, generating a mix of equipment, consumables and service revenue streams over time. Background and price data on Hologic. Further news, key figures and historical share price data on Hologic are available in the dedicated topic section on ad-hoc-news.de and via the company's Investor Relations page. The products behind the stock. One of Hologic's flagship product families is its 3D mammography platform, marketed under the Selenia Dimensions brand for digital breast tomosynthesis and related imaging workflows.Hologic Selenia Dimensions product page These systems are used in breast screening programs to detect cancer at earlier stages through high-resolution imaging and advanced reconstruction software. Where the shares trade today. The Hologic shares (US4364401012) trade on NASDAQ in the United States, with the price quoted in US dollars at the latest available close. The listing places the company among a broad group of healthcare and medical technology stocks monitored by international investors. Key data on the Hologic shares. * Company: Hologic, Inc. * ISIN: US4364401012 * WKN: 885423 * Ticker: HOLX * Trading venue: NASDAQ * Price (as of 2026-06-23, 16:00): 75.00 USD * Market cap: 18,000,000,000 USD (as of 2026-06-23) * Sector / industry: Health Care / Medical Technology * Index membership: S&P 500 * Next earnings date: 2026-07-31 Disclaimer: This text is for informational purposes only and does not constitute investment advice, tax advice or a recommendation to buy or sell financial instruments. All data have been compiled with care but without guarantee. Hologic stock: new analysis - 24 june. Fresh Hologic information released. What's the impact for investors? Our latest independent report examines recent figures and market trends. en | US4364401012 | HOLOGIC | boerse | 69616470 | bgmi